Pyxis Oncology is trading 5.41% down at $1.75, amid broader market pressure after hotter-than-expected September inflation renewed interest-rate concerns. - Reuters reported a market selloff and rising rate-hike expectations, the clearest available context for the decline, not a confirmed company-specific cause. - No new company-specific announcement surfaced for October 14; the company’s latest listed release is dated October 2.